Inhibikase Therapeutics Grants Inducement Shares to New Hires

The biotech firm awarded stock options to five new non-executive employees.

Apr. 3, 2026 at 6:45pm

Got story updates? Submit your updates here. ›

A photorealistic studio still-life featuring a stack of stock certificates, a pen, and a calculator on a clean, monochromatic background, symbolizing corporate finance and talent acquisition.Inhibikase Therapeutics' equity-based incentives aim to build a strong team as the company advances its pipeline of PAH treatments.Wilmington Today

Inhibikase Therapeutics, a clinical-stage pharmaceutical company developing treatments for pulmonary arterial hypertension (PAH), announced that it granted non-qualified stock options to purchase up to an aggregate of 685,718 shares of the company's common stock to five newly-hired non-executive employees. The options were granted under the company's 2026 Inducement Equity Plan, with an exercise price of $1.68 per share.

Why it matters

The inducement grants are a common practice for public companies to attract and retain talent, especially in competitive industries like biotech. Inhibikase's announcement highlights its efforts to build out its team as it advances its lead PAH drug candidate, IKT-001, through late-stage clinical trials.

The details

The stock options granted to the new employees will vest over time, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in 36 equal monthly installments thereafter. The options have a 10-year term and are subject to the terms of Inhibikase's Inducement Equity Plan and the specific award agreements.

  • The grants were effective as of March 31, 2026.

The players

Inhibikase Therapeutics, Inc.

A clinical-stage pharmaceutical company developing treatments for pulmonary arterial hypertension (PAH).

Got photos? Submit your photos here. ›

The takeaway

Inhibikase's inducement grants demonstrate the company's commitment to building a strong team as it advances its pipeline of PAH treatments. These types of equity awards are a common tool for public biotech firms to attract top talent in a competitive industry.